Bonus Material-31_Lung Cancer Part II

Pdf Summary

This comprehensive Lung Cancer Board Review by Dr. Gerard A. Silvestri covers diagnosis, staging, and treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

<strong>Invasive Staging:</strong> Accurate mediastinal lymph node staging is critical. CT and PET scans show sensitivities of ~55-80% and specificities ~81-88%. Tissue sampling methods include mediastinoscopy, EBUS, EUS, and transbronchial needle aspiration (TBNA), with combined EBUS/EUS offering ~91% sensitivity and 100% specificity. Guidelines recommend minimally invasive needle techniques over surgery when N2/N3 nodal involvement is suspected.

<strong>Stage 1 NSCLC Treatment:</strong> Lobectomy with mediastinal node dissection remains standard. Video-assisted thoracoscopic surgery (VATS) yields similar survival but with less pain, quicker recovery, and better morbidity profiles than open surgery. Sublobar resection for tumors ≤2 cm showed comparable 5-year survival and recurrence rates in a large RCT. For inoperable patients, stereotactic body radiotherapy (SBRT) delivers high-dose radiation precisely with fewer toxicities.

<strong>Adjuvant Chemotherapy:</strong> Recommended for Stage II and IIIA NSCLC post-surgery to reduce relapse risk; not advised for Stage IA due to lack of benefit. Platinum-based doublets are standard.

<strong>Stage II and IIIA Treatment:</strong> Surgery plus adjuvant chemotherapy or targeted therapy (EGFR or ALK positive) is standard. Neoadjuvant chemo-immunotherapy followed by surgery is increasingly used, especially with Checkmate 816 showing improved event-free survival and pathologic response with nivolumab plus chemotherapy. For unresectable Stage III, concurrent chemoradiotherapy followed by consolidation immunotherapy (e.g., durvalumab in the PACIFIC trial) improves progression-free survival.

<strong>Pancoast Tumors:</strong> Require induction chemoradiotherapy followed by en bloc resection when possible, improving 5-year survival up to 54%.

<strong>Stage IV NSCLC:</strong> Treatment is personalized based on molecular biomarkers (EGFR, ALK, ROS1, PD-L1, KRAS G12C, etc.) guiding targeted therapies (tyrosine kinase inhibitors) or immunotherapy. TKIs like osimertinib in EGFR mutants and alectinib for ALK rearrangements improve progression-free survival and CNS protection.

<strong>Small Cell Lung Cancer (SCLC):</strong> Usually systemic at diagnosis; extensive disease treated with platinum-etoposide chemotherapy plus immunotherapy. Limited stage adds concurrent thoracic radiation. Prophylactic cranial irradiation reduces brain metastases in responders.

<strong>Immunotherapy Toxicities:</strong> Immune-related adverse events (IRAEs) mostly affect lungs; graded management ranges from observation to corticosteroids and therapy discontinuation.

Overall, lung cancer management integrates precise invasive staging, surgery, radiation, chemotherapy, targeted therapy, and immunotherapy tailored to stage and molecular profiles to optimize outcomes.

Meta Tag

Concept Mediastinal Staging

Concept Lung Cancer

Concept Stage I Non-Small Cell Lung Cancer

Concept Lobectomy

Concept Resectable Non-Small Cell Lung Cancer

Keywords

lung cancer

non-small cell lung cancer

small cell lung cancer

mediastinal staging

EBUS EUS

lobectomy

SBRT

adjuvant chemotherapy

immunotherapy

targeted therapy

Mediastinal Staging

Lung Cancer

Stage I Non-Small Cell Lung Cancer

Lobectomy

Resectable Non-Small Cell Lung Cancer